Antibody–Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond—A 2023 Review

Antibody–drug conjugates (ADCs) are revolutionizing cancer treatment, adding another important new class of systemic therapy. ADCs are a specially designed class of therapeutics that target cells expressing specific cancer antigens using directed antibody–drug delivery and release a cytotoxic chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Tian, Ali, Sanji, Mata, Danilo Giffoni M. M., Lohmann, Ana Elisa, Blanchette, Phillip S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378319/
https://www.ncbi.nlm.nih.gov/pubmed/37504334
http://dx.doi.org/10.3390/curroncol30070474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378319/
https://www.ncbi.nlm.nih.gov/pubmed/37504334
http://dx.doi.org/10.3390/curroncol30070474

Ejemplares similares